Recent policies reflect China’s goal of promoting patients’ access to innovative drugs. Noteworthy policy items include: State Council releases 2019 Work Tasks to Deepen Healthcare Reform Center for Drug Evaluation releases the first real-world evidence application policy in China for public comment National Health Commission initiates pilot programs to develop hospital…
Recent policies reflect China’s goal of promoting patients’ ac- cess to innovative drugs. Note- worthy policy items include: NMPA issued China Drug Regulatory Scientific Action Plan NHSA released Work Plan for the 2019 Adjustment to the National Reimbursement Drug List (NRDL) NHSA and MoF jointly released Notice on Key Tasks…
Recent policies reflect China’s goal of promoting patients’ accessto innovative drugs. Noteworthy policy items include: NHSA released Work Plan for the 2019 Adjustment to the National Reimbursement Drug List for public comment NHSA released Opinions on the Implementation of National Centralized Procurement and Supporting Medical Insurance Measures NHC Published Measures…
RECENT HEALTHCARE DEVELOPMENTS Recent policies reflect China’s goal of promoting patients’ access to innovative drugs. Noteworthy policy items include: The 2018 version of the Essential Drug List (EDL) was approved National Reimbursement Drug List (NRDL) Negotiation Results Released NMPA released List of Medical Devices Exempted from Clinical Trials Zhang Mao…
RECENT HEALTHCARE DEVELOPMENTS Recent policies reflect China’s goal of promoting patients’ access to innovative drugs. Noteworthy policy items include: State Council released the Plan for Reforming the Division of Fiscal Administration Power and Expenditure Responsibilities between the Central and Local Level in the Area of Healthcare China’s Politburo Held a…
Recent policies reaffirm China’s goal to further enhance patients’ access and signal certain reform directions in the future. Noteworthy policy items include: Premier Li Keqiang announced three tasks to promote patient access to anti-cancer drugs and reduce drug prices NDRC and MOFCOM released Negative List 2018 Version SDA released 2017…
Recent policies provide detailed instruction to promote the implementation of preferential policies of high-value drugs. Noteworthy policy items include: President Xi emphasized promoting a Comprehensive Regulatory System of Healthcare at the second meeting of the Central Leading Committee for Comprehensively Deepening Reform State Council released Plans for Deepening Reforms and…
Recent policy developments show Chinese government’s efforts in encouraging pharmaceutical innovation, improving the drug review and approval, and promoting the development of healthcare professionals. Recent noteworthy policy items include: CFDA and MOST jointly released Guiding Opinions on Strengthening and Promoting Technological Innovation in the Food and Drug Sector The China…
These macro-level policy developments indicate the Chinese government’s decision to further open the economy, and to place increasing emphasis on improving people’s livelihood. Noteworthy policy items include: President Xi Jinping delivered a keynote speech at the opening ceremony of the Boao Forum for Asia (BFA) Annual Conference 2018 MOF released…
Recent policy developments show the government’s concern over controlling medical expenditure, enhancing drug safety, and increasing international participation. Recent noteworthy policy items include: * NHFPC released 2016 China Health and Family Planning Development Report * State Council released Measures to Promote Foreign Investment * CFDA released the Circular on the…
